Exosome as the Prognostic and Predictive Biomarker in EBC Patients

Samsung Medical Center

Status: Active, not recruiting

Conditions: HER2-positive Breast Cancer; Triple Negative Breast Cancer

Treatments: Procedure: exosome and ctDNA evaluation

Study type: Interventional

Funder types: Other

Identifiers

NCT05955521

EXO_Breast

Details and patient eligibility

About

This study is the experimental study for serial ctDNA and exosome evaluation in EBC patients

Enrollment: 200 patients

Sex: Female

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Early breast cancer
• Planned neoadjuvant chemotherapy
• Triple negative breast cancer or HER2-positive breast cancer

Exclusion criteria

• Stage IV breast cancer
• Hormone receptor positive breast cancer

Trial design

Primary purpose: Screening

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

200 participants in 1 patient group

CtDNA/Exosome evaluation

Experimental group

Treatment:

Procedure: exosome and ctDNA evaluation